ERBB2 and breast cancer: In the landmark adjuvant BCIRG-006 trial which randomized 3222 patients with operable HER2-positive breast cancer to either AC-T (doxorubicin/cyclophosphamide followed by docetaxel), AC-TH (doxorubicin/cyclophosphamide followed by docetaxel/trastuzumab), or TCbH (doxetaxel/carboplatin/trastuzumab), 10-year DFS and OS were numerically very similar in the two trastuzumab containing arms.